Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
[Editor's note: This is part two of a two-part story from Bio Korea; part one was published in PharmAsia News, Oct. 12, 2008.]
You may also be interested in...
South Korea’s BiocurePharm To Produce Biosimilars In Thailand
SEOUL - South Korean biopharmaceutical company BiocurePharm signed a memorandum of understanding with Thailand pharmaceutical distributor Kwang Tiang Dispensary to build a $20 million plant in Thailand to produce five types of biosimilar products for anemia and hepatitis, BiocurePharma announced Nov. 13
South Korea’s BiocurePharm To Produce Biosimilars In Thailand
SEOUL - South Korean biopharmaceutical company BiocurePharm signed a memorandum of understanding with Thailand pharmaceutical distributor Kwang Tiang Dispensary to build a $20 million plant in Thailand to produce five types of biosimilar products for anemia and hepatitis, BiocurePharma announced Nov. 13
Merck To Close Plant In South Korea As Part Of Global Supply Strategy
SHANGHAI - Merck will close down its plant in South Korea, the U.S.-based drug maker said Nov. 3